

XII NIBIT Meeting
Siena, October 9-11 2014
Hotel Garden
Viale Custoza 2, Siena

Thursday October 9

12:00 *Arrival/Registration/Light Lunch*

14:00 Welcome addresses

Session 1. Mutated tumor antigens and adoptive cell therapy in the clinics
Chair: Per Thor Straten (Copenhagen) and Giorgio Parmiani (Milan/Siena)

14.15 Paul Robbins (Bethesda): Targeting mutated antigens by adoptive cell therapy.

14:40 Anna Mondino (Milan): Novel strategies to improve adoptive T cell therapy for solid tumors

15:05 Per Thor Straten (Copenhagen): Cancer therapy using tumor infiltrating lymphocytes (TIL) for adoptive transfer: prospects and pitfalls

15:30 Selected Abstract:

15:45 Selected Abstract:

16:00 Coffee break

Session 2. Targeting cancer stem cells for immunotherapy
Chair: Ruggero De Maria (Rome), Matteo Bellone (Milan)

16:30 Michele Cioffi (Madrid): Biology of cancer stem cells: an up-date

16:55 Giorgio Stassi (Palermo): Cancer stem cells: from bench to bedside

17:20 Serena Pellegatta (Milan): Immunotherapy with dendritic cells loaded with glioblastoma stem-cells: from preclinical to clinical studies

17:45 Selected Abstract:

18:00 Selected Abstract

18:15 General Assembly of the NIBIT

20:00 Dinner

Friday October 10***Session 3. Tumor microenvironment and metabolism****Chair: Paolo Dellabona (Milan) and Ruggero Ridolfi (Meldola)*

- 8:30 Federica Marchesi (Milan): Tertiary Lymphoid Tissue: a key player of the tumor microenvironment
- 8:55 Claudio Tripodo (Palermo): Common stromal motifs influence the pathobiology of myeloid and lymphoid malignancies
- 9:20 Vincenzo Russo (Milan): LXR dependent and independent effects of oxysterols on immunity and tumor growth
- 9:45 Maria Pia Protti (Milan): Th22 cells in multiple myeloma: frequency and tumor promoting function
- 10:10 Selected Abstract
- 10:25 Selected Abstract

10.40 Coffee break***Session 4. New developments in immuno-oncology****Chair: Paola Zanovello (Padua) and Massimo Di Nicola (Milan)*

- 11:00 Davide Bedognetti (Doha): Illuminating the molecular mechanisms of response to cancer immunotherapy
- 11:25 Soldano Ferrone (Boston): HLA class I antigen and PD-L1 expression and clinical course of the disease in intra hepatic cholangiocarcinoma
- 11:50 Hervé Fridman (Paris): Driving immunotherapy by tumor phenotype
- 12:15 Barbara Seliger (Halle): Role of microRNAs for immune escape of tumors
- 12:40 Selected Abstract
- 12:55 Selected Abstract

13:10 Lunch

Session 5. Vaccines: Pitfalls and promises

Chair: Enrico Proietti (Rome) and Pier Francesco Ferrucci (Milan)

- 14:30 Giorgio Parmiani (Milan): Cancer vaccines: still promising?
- 14:55 Carl Figdor (Nijmegen): Dendritic cells in cancer-immunotherapy: next steps to take
- 15:20 Pedro Romero (Lausanne): Peptide vaccinations of cancer patients

Invited Abstract

- 15:45 Elisabeth Griffith (Buffalo): Decitabine induced NY-ESO1 expression as a therapeutic target in myelodysplasia: preliminary results from a phase I study
- 16:00 Selected Abstract

16:15 Coffee break

Session 6. Checkpoint blockade and targeted therapies in melanoma and other tumors

Chairs: Michele Maio (Siena) and Paola Queirolo (Genoa)

- 16:30 Jeffrey Weber (Tampa): Overview of check-point blockade agents
- 16:55 TBD: Checkpoint blockade in thoracic malignancies
- 17:20 Ramy Ibrahim (Gaithersburg): MedImmune Phase I studies
- 17:45 Michele del Vecchio (Milano) BRAF and MEK inhibitors

Invited Abstract

- 18:10 Pierre Ferrè (Gèneve): W014A, a PD-1 decoy peptide blocking both PD-1 immune checkpoint ligands, PD-L1 and PD-L2

Selected Abstract

18:25

20:00 Social Dinner

Saturday October 11***Session 7: Prognostic and predictive biomarkers in bio - immunotherapy****Chairs: Licia Rivoltini (Milan) and Graham Pawelec (Tübingen)*

- 8:30 Matteo Ramazzotti (Firenze): A Systems Level approach for the discovery of prognostic signatures through big data analyses
- 08:55 Andrea Anichini (Milan): Mechanisms of susceptibility and/or resistance to ipilimumab?
- 9:20 Benjamin Weide (Tübingen): Biomarkers and survival in the course of ipilimumab
- 9:45 Cristina Maccalli (Siena): Immunologic biomarkers and response to therapy

10: 10 Coffee break***Session 8. Ongoing and prospective NIBIT activities and collaborations****Chair: Alberto Amadori (Padua) and Alessandro Testori (Milan)*

- 10:30 Anna Maria Di Giacomo (Siena): NIBIT clinical studies
- 10:45 Diana Giannarelli (Rome): Design of immunotherapeutic studies
- 11:00 Luigi Buonaguro (Naples): Cancer vaccines in hepatocarcinoma
- 11:15 Massimo Guidoboni (Meldola): The NIBIT effect: how the Network can promote synergies in developing cellular therapies
- 11:30 TBD
- 11:45 TBD

12:00 Round Table: Clinical research on cancer Bio-Immunotherapy in Italy: a near miss or an opportunity to catch?"***13:30 Lunch******Adjourn***